Ongoing clinical trials in molecular imaging and radiotheranostics. Sorted by date of last update.
A Study of Lu-177-DTPA-SC16.56 in People with Neuroendocrine Carcinomas of the Lung and Prostate
Phase 1
Last update: April 14
Study in Children and Adolescents of Lu-177-DOTATATE (Lutathera®) Combined with the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). (LUPARPED)
A Phase Ib/II Open-label Study of AMO959 with Lutetium (Lu-177) Vipivotide Tetraxetan (AAA617) in Combination with ARPI in Adult Participants with PSMA-positive mCRPC
Lu-177-DOTA-EB-TATE in Adult Patients with Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
Lu-177-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours (LuPARP)
A Phase 1 Study of Ga-68-R11228 and Lu-177-R11228 in Breast Cancer
Last update: April 13
Real-world Experience with Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer
N/A
Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu-177 Dotatate) for Pancreatic Neuroendocrine Tumors
Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used with Targeted Radiation-based Treatment (Lutetium Lu-177 Dotatate), Compared to Lutetium Lu-177 Dotatate Alone for Metastatic Neuroendocrine Tumors
Phase 2
Comparing Retreatment of Lu-177-DOTATATE PRRT versus the Usual Treatment in Patients with Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial